| Bioactivity | Eragidomide (CC-90009) is a first-in-class GSPT1-selective cereblon (CRBN) E3 ligase modulator, acts as a molecular glue. Eragidomide coopts the CRL4CRBN to selectively target GSPT1 for ubiquitination and proteasomal degradation[1][2]. | ||||||||||||
| Invitro | Depletion of GSPT1 by Eragidomide rapidly induces acute myeloid leukemia (AML) apoptosis, reducing leukemia engraftment and leukemia stem cells (LSCs) in large-scale primary patient xenografting of 35 independent AML samples. Eragidomide activity is mediated by multiple layers of signaling networks and pathways within AML blasts and LSCs[1]. | ||||||||||||
| Name | Eragidomide | ||||||||||||
| CAS | 1860875-51-9 | ||||||||||||
| Formula | C22H18ClF2N3O4 | ||||||||||||
| Molar Mass | 461.85 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Eragidomide
CAS: 1860875-51-9 F: C22H18ClF2N3O4 W: 461.85
Eragidomide (CC-90009) is a first-in-class GSPT1-selective cereblon (CRBN) E3 ligase modulator, acts as a molecular glue
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.